FibroBiologics, Inc. Common Stock - FBLG - Fundamentals

Feel free to try out our engine!Whenever you're ready, pick a plan!

Best investment/trading ideas for the weekJoin our free webinar on April8,2026.

Combo Screeneris now available. Explore seasonality and pattern opportunities across asset classes.

Explore now

‌
‌

‌

Let's get started...

‌

Breakdown	2020 12/31	2021 12/31	2022 12/31	2023 12/31	2024 12/31	2025 12/31	TTM
REVENUE	0	0	0	0	0	0	--	📊
Revenue Growth (1Y)	--	--	--	--	--	--	--	📊
Revenue Growth (5Y)	--	--	--	--	--	--	--	📊
Revenue Growth (10Y)	--	--	--	--	--	--	--	📊
Cost of Revenue	0	0	0	0	1	0	--	📊
Cost of Revenue Growth (1Y)	--	--	--	+364.89%	+31.12%	-100.00%	--	📊
Cost of Revenue Growth (5Y)	--	--	--	--	--	--	--	📊
Cost of Revenue Growth (10Y)	--	--	--	--	--	--	--	📊
Gross Profit	0	0	-0	-0	-1	0	--	📊
Gross Profit Growth (1Y)	--	--	--	-364.89%	-31.12%	+100.00%	--	📊
Gross Profit Growth (5Y)	--	--	--	--	--	--	--	📊
Gross Profit Growth (10Y)	--	--	--	--	--	--	--	📊
Operating Expenses	1	2	4	9	14	17	17	📊
Operating Expenses Growth (1Y)	--	+34.99%	+177.12%	+103.27%	+54.54%	+21.20%	--	📊
Operating Expenses Growth (5Y)	--	--	--	--	+1075.11%	+955.07%	--	📊
Operating Expenses Growth (10Y)	--	--	--	--	--	--	--	📊
Sell General Administrative	1	1	3	7	9	9	9	📊
Research and Development	1	1	1	2	5	7	7	📊
Other Income Expenses	0	0	0	0	0	0	--	📊
EBITDA	0	-2	-4	-16	-14	-17	-17	📊
EBITDA Growth (1Y)	--	--	-177.12%	-263.62%	+13.61%	-21.20%	--	📊
EBITDA Growth (5Y)	--	--	--	--	--	-955.07%	--	📊
EBITDA Growth (10Y)	--	--	--	--	--	--	--	📊
Depreciation and Amortization	1	0	0	0	1	0	1	📊
Operating Income	-1	-2	-4	-9	-14	-17	-17	📊
Operating Income Growth (1Y)	--	-34.99%	-183.08%	-98.99%	-54.54%	-21.20%	--	📊
Operating Income Growth (5Y)	--	--	--	--	-1075.11%	-955.07%	--	📊
Operating Income Growth (10Y)	--	--	--	--	--	--	--	📊
Interest Expense	0	0	1	0	0	-0	--	📊
Pre Tax Income	-1	-2	-5	-16	-11	-19	-19	📊
Tax Provision	0	0	0	0	0	0	--	📊
NET INCOME	-1	-2	-5	-16	-11	-19	-19	📊
Net Income Growth (1Y)	--	-35.33%	-223.70%	-221.91%	+32.30%	-67.06%	--	📊
Net Income Growth (5Y)	--	--	--	--	-854.75%	-1078.63%	--	📊
Net Income Growth (10Y)	--	--	--	--	--	--	--	📊
Basic EPS	-0.04	-0.05	-0.16	-0.59	-0.34	-0.42	-0.42	📊
Diluted EPS	-0.04	-0.05	-0.16	-0.68	-0.34	-0.42	-0.42	📊
Basic Average Shares	32	32	32	32	33	45	41	📊
Diluted Average Shares	32	32	32	28	33	45	41	📊

Breakdown	2020 12/31	2021 12/31	2022 12/31	2023 12/31	2024 12/31	2025 12/31	TTM
REVENUE	0	0	0	0	0	0	--	📊
Revenue Growth (1Y)	--	--	--	--	--	--	--	📊
Revenue Growth (5Y)	--	--	--	--	--	--	--	📊
Revenue Growth (10Y)	--	--	--	--	--	--	--	📊
Cost of Revenue	0	0	0	0	1	0	--	📊
Cost of Revenue Growth (1Y)	--	--	--	+364.89%	+31.12%	-100.00%	--	📊
Cost of Revenue Growth (5Y)	--	--	--	--	--	--	--	📊
Cost of Revenue Growth (10Y)	--	--	--	--	--	--	--	📊
Gross Profit	0	0	-0	-0	-1	0	--	📊
Gross Profit Growth (1Y)	--	--	--	-364.89%	-31.12%	+100.00%	--	📊
Gross Profit Growth (5Y)	--	--	--	--	--	--	--	📊
Gross Profit Growth (10Y)	--	--	--	--	--	--	--	📊
Operating Expenses	1	2	4	9	14	17	17	📊
Operating Expenses Growth (1Y)	--	+34.99%	+177.12%	+103.27%	+54.54%	+21.20%	--	📊
Operating Expenses Growth (5Y)	--	--	--	--	+1075.11%	+955.07%	--	📊
Operating Expenses Growth (10Y)	--	--	--	--	--	--	--	📊
Sell General Administrative	1	1	3	7	9	9	9	📊
Research and Development	1	1	1	2	5	7	7	📊
Other Income Expenses	0	0	0	0	0	0	--	📊
EBITDA	0	-2	-4	-16	-14	-17	-17	📊
EBITDA Growth (1Y)	--	--	-177.12%	-263.62%	+13.61%	-21.20%	--	📊
EBITDA Growth (5Y)	--	--	--	--	--	-955.07%	--	📊
EBITDA Growth (10Y)	--	--	--	--	--	--	--	📊
Depreciation and Amortization	1	0	0	0	1	0	1	📊
Operating Income	-1	-2	-4	-9	-14	-17	-17	📊
Operating Income Growth (1Y)	--	-34.99%	-183.08%	-98.99%	-54.54%	-21.20%	--	📊
Operating Income Growth (5Y)	--	--	--	--	-1075.11%	-955.07%	--	📊
Operating Income Growth (10Y)	--	--	--	--	--	--	--	📊
Interest Expense	0	0	1	0	0	-0	--	📊
Pre Tax Income	-1	-2	-5	-16	-11	-19	-19	📊
Tax Provision	0	0	0	0	0	0	--	📊
NET INCOME	-1	-2	-5	-16	-11	-19	-19	📊
Net Income Growth (1Y)	--	-35.33%	-223.70%	-221.91%	+32.30%	-67.06%	--	📊
Net Income Growth (5Y)	--	--	--	--	-854.75%	-1078.63%	--	📊
Net Income Growth (10Y)	--	--	--	--	--	--	--	📊
Basic EPS	-0.04	-0.05	-0.16	-0.59	-0.34	-0.42	-0.42	📊
Diluted EPS	-0.04	-0.05	-0.16	-0.68	-0.34	-0.42	-0.42	📊
Basic Average Shares	32	32	32	32	33	45	41	📊
Diluted Average Shares	32	32	32	28	33	45	41	📊

FibroBiologics, Inc. Common Stock - FBLG - Fundamentals - Financial Statements

Ex-Dividend date	--
Payment date	--
Annual Dividend	--
Dividend Yield	--
Shareholders Yield	15.46%
Next Earnings	--
Market cap	59.40M (USD)
EPS (TTM)	-0.42 ($)
P/E (TTM)	-3.17 ($)
Last Close	1.33

Next Earnings	--
Market cap	59.40M (USD)
EPS (TTM)	-0.42 ($)
P/E (TTM)	-3.17 ($)
Last Close	1.33 ($)

Ex-Dividend date	--
Payment date	--
Annual Dividend	--
Dividend Yield	--
Shareholders Yield	15.46%
Next Earnings	--
Market cap	59.40M (USD)
EPS (TTM)	-0.42 ($)
P/E (TTM)	-3.17 ($)
Last Close	1.33

Next Earnings	--
Market cap	59.40M (USD)
EPS (TTM)	-0.42 ($)
P/E (TTM)	-3.17 ($)
Last Close	1.33 ($)